CMS Entry id: 2710 | Channel: News landing page | Template: news/index



3 January 2018

WEBINAR: Overcoming Methodological Challenges to Enhance Study Success in Schizophrenia trials

Join Dr. Kiri Granger, Director of Neuroscience, Cambridge Cognition and Dr. Steve Brannan, Chief Medical Officer, ‎Karuna Pharmaceuticals Inc. for a live discussion on improving clinical trial success in schizophrenia.

The webinar takes place on Tuesday, January 30, 2018 at 11am EST (4pm GMT).

30 November 2017

CANTAB Mobile and CANTAB Insight are now TGA approved for Australian market

We’re delighted to announce that both CANTAB Mobile and CANTAB Insight medical devices, designed for the assessment of cognitive health in clinical practice, have been approved for marketing in Australia by the Therapeutic Goods Administration (TGA) (ARTG No. 294119).

28 November 2017

Cognition Kit wearable technology demonstrates high compliance among patients with major depressive disorder (MDD)

​At the 2017 International CNS Summit in Boca Raton, Florida, we were pleased to release the positive results from a pilot study into the evaluation of cognition and mood using wearable technology in patients with MDD.

13 November 2017

Join us at the CNS Summit 2017

Cambridge Cognition are attending the Collaborating for Novel Solutions (CNS) Summit: 16th-19th November 2017. 

8 November 2017

Hogrefe becomes exclusive distributor of CANTAB in Finland

We’re pleased to announce that Hogrefe Psykologien Kustannus Oy is now an exclusive distributor of CANTAB software products for use in Finland by academic researchers and healthcare professionals.

6 November 2017

Speech recognition and online assessments: the future for clinical trials in Alzheimer’s disease?

New data demonstrates possibility for speech recognition and online assessments to enhance clinical trials in Alzheimer’s disease.

12 September 2017

Award of funding to develop novel digital health system

A new system being developed by Cambridge Cognition with Innovate UK funding will provide a non-invasive, inexpensive means of accurately monitoring levels of pain by combining artificial intelligence technology and cognitive neuroscience.

Share this